The MDS Beacon™

Potential MDS Treatment Completed Phase 2 Trial For AML — On October 28, Cyclacel Pharmaceuticals, Inc. announced that the drug sapacitabine, which is being tested for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and several other cancers, successfully prolonged survival of AML patients ages 70 years or older. Under two of the dosing schedules tested, thirty percent of the newly diagnosed or recently relapsed AML patients lived longer than one year. Sapacitibine is an oral agent that interferes with both DNA synthesis and cell division. Cyclacel is currently recruiting AML and elderly MDS patients for a Phase 2 clinical trial testing sapacitibine. For more information, please see the Cyclacel press release.

5th International Congress On Myeloproliferative Diseases And Myelodysplastic Syndromes — On November 5 through 7, the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes will be held in New York City. The conference is geared toward medical professionals and will feature updates and discussions about blood cancer research. To register, or for more information, please see the Congress Web site.

The Unknown Side Effects Of Cancer — The Leukemia & Lymphoma Society (LLS) is sponsoring an educational program that will help cancer patients confront the psychological and emotional difficulties that often accompany cancer. The event will be held on Thursday, November 12, from 11:30 a.m. to 2:30 p.m. in Rockford, IL. For more information, please see the LLS Web site.

For a more detailed listing of MDS-related events, please check the MDS Beacon Events Calendar.